Literature DB >> 229254

The 55K protein on the 5' termini of adenovirus type 2 DNA is unrelated to virus-coded candidate transformation proteins (E1-53K, E1-40K-50K) and DNA-binding proteins (E2-42K/47K/73K).

M Green, W S Wold, K H Brackmann, M A Cartas.   

Abstract

A polypeptide of 55,000 daltons (55K) is linked, probably covalently, to the K' termini of adenovirus type 2 DNA. The 55K polypeptide is synthesized during early stages of infection (T. Yamashita, M. Arens, and M. Green, J. Virol. 30: 497-507, 1979) and thus may function in viral DNA replication, gene regulation, or cell transformation. Several virus-coded early polypeptides have been identified that could correspond to the terminal 55K, including the E1-40K-50K and E1-53K candidate transformation polypeptides and the E2-42K/47K/73K single-stranded DNA-binding polypeptide. We show here that two-dimensional tryptic [35S]methionine-peptide maps of the terminal 55K differ completely from [35S]methionine-peptide maps of four related E1-40K-50K polypeptides, the E1-53K, and the related E2-42K, E2-47K, and E2-73K polypeptides. We conclude that the terminal 55K polypeptide does not correspond to any of the known virus-coded early polypeptides.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 229254      PMCID: PMC353511     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  16 in total

1.  Similarity of DNAs isolated from tumor-inducing viruses of human and animal origin.

Authors:  M GREEN; M PINA
Journal:  Proc Natl Acad Sci U S A       Date:  1963-07       Impact factor: 11.205

2.  Protein synthesized early after infection is linked to the termini of adenovirus type 2 DNA synthesized in vivo and in vitro.

Authors:  T Yamashita; M Arens; M Green
Journal:  J Virol       Date:  1979-05       Impact factor: 5.103

3.  Radioiodination of proteins in single polyacrylamide gel slices. Tryptic peptide analysis of all the major members of complex multicomponent systems using microgram quantities of total protein.

Authors:  J H Elder; R A Pickett; J Hampton; R A Lerner
Journal:  J Biol Chem       Date:  1977-09-25       Impact factor: 5.157

4.  Identification of a protein linked to the ends of adenovirus DNA.

Authors:  D M Rekosh; W C Russell; A J Bellet; A J Robinson
Journal:  Cell       Date:  1977-06       Impact factor: 41.582

5.  Specific interaction of a protein(s) at or near the termini of adenovirus 2 DNA.

Authors:  R Padmanabhan; R V Padmanabhan
Journal:  Biochem Biophys Res Commun       Date:  1977-04-25       Impact factor: 3.575

6.  Thirty-one human adenovirus serotypes (Ad1-Ad31) form five groups (A-E) based upon DNA genome homologies.

Authors:  M Green; J K Mackey; W S Wold; P Rigden
Journal:  Virology       Date:  1979-03       Impact factor: 3.616

7.  The isolation and identification of the adenovirus group C tumor antigens.

Authors:  A Levinson; A J Levine
Journal:  Virology       Date:  1977-01       Impact factor: 3.616

8.  Evidence for blocked 5'-termini in human adenovirus DNA.

Authors:  E A Carusi
Journal:  Virology       Date:  1977-01       Impact factor: 3.616

9.  Adenovirus type 2 early polypeptides immunoprecipitated by antisera to five lines of adenovirus-transformed rat cells.

Authors:  W S Wold; M Green
Journal:  J Virol       Date:  1979-04       Impact factor: 5.103

10.  Viral DNA sequences and gene products in hamster cells transformed by adenovirus type 2.

Authors:  K Johansson; H Persson; A M Lewis; U Pettersson; C Tibbetts; L Philipson
Journal:  J Virol       Date:  1978-09       Impact factor: 5.103

View more
  2 in total

1.  Analysis of the DNA-terminal protein from different serotypes of human adenovirus.

Authors:  D Rekosh
Journal:  J Virol       Date:  1981-10       Impact factor: 5.103

2.  Immunological and chemical identification of intracellular forms of adenovirus type 2 terminal protein.

Authors:  M Green; J Symington; K H Brackmann; M A Cartas; H Thornton; L Young
Journal:  J Virol       Date:  1981-11       Impact factor: 5.103

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.